Titre : Leucémies

Leucémies : Questions médicales fréquentes

Termes MeSH sélectionnés :

Informatics
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Leucémies : Questions médicales les plus fréquentes", "headline": "Leucémies : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Leucémies : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-29", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Leucémies" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs par type histologique", "url": "https://questionsmedicales.fr/mesh/D009370", "about": { "@type": "MedicalCondition", "name": "Tumeurs par type histologique", "code": { "@type": "MedicalCode", "code": "D009370", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Leucémie myéloïde", "alternateName": "Leukemia, Myeloid", "url": "https://questionsmedicales.fr/mesh/D007951", "about": { "@type": "MedicalCondition", "name": "Leucémie myéloïde", "code": { "@type": "MedicalCode", "code": "D007951", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Leucémie aigüe myéloïde", "alternateName": "Leukemia, Myeloid, Acute", "url": "https://questionsmedicales.fr/mesh/D015470", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe myéloïde", "code": { "@type": "MedicalCode", "code": "D015470", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Leucémie aiguë à basophiles", "alternateName": "Leukemia, Basophilic, Acute", "url": "https://questionsmedicales.fr/mesh/D015471", "about": { "@type": "MedicalCondition", "name": "Leucémie aiguë à basophiles", "code": { "@type": "MedicalCode", "code": "D015471", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.125" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe à éosinophiles", "alternateName": "Leukemia, Eosinophilic, Acute", "url": "https://questionsmedicales.fr/mesh/D015472", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe à éosinophiles", "code": { "@type": "MedicalCode", "code": "D015472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.300" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe mégacaryoblastique", "alternateName": "Leukemia, Megakaryoblastic, Acute", "url": "https://questionsmedicales.fr/mesh/D007947", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe mégacaryoblastique", "code": { "@type": "MedicalCode", "code": "D007947", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.450" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe monoblastique", "alternateName": "Leukemia, Monocytic, Acute", "url": "https://questionsmedicales.fr/mesh/D007948", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe monoblastique", "code": { "@type": "MedicalCode", "code": "D007948", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.484" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aiguë promyélocytaire", "alternateName": "Leukemia, Promyelocytic, Acute", "url": "https://questionsmedicales.fr/mesh/D015473", "about": { "@type": "MedicalCondition", "name": "Leucémie aiguë promyélocytaire", "code": { "@type": "MedicalCode", "code": "D015473", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.700" } } } ] }, { "@type": "MedicalWebPage", "name": "Leucémie aiguë à basophiles", "alternateName": "Leukemia, Basophilic, Acute", "url": "https://questionsmedicales.fr/mesh/D015471", "about": { "@type": "MedicalCondition", "name": "Leucémie aiguë à basophiles", "code": { "@type": "MedicalCode", "code": "D015471", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.125" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe à éosinophiles", "alternateName": "Leukemia, Eosinophilic, Acute", "url": "https://questionsmedicales.fr/mesh/D015472", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe à éosinophiles", "code": { "@type": "MedicalCode", "code": "D015472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.300" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe mégacaryoblastique", "alternateName": "Leukemia, Megakaryoblastic, Acute", "url": "https://questionsmedicales.fr/mesh/D007947", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe mégacaryoblastique", "code": { "@type": "MedicalCode", "code": "D007947", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.450" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe monoblastique", "alternateName": "Leukemia, Monocytic, Acute", "url": "https://questionsmedicales.fr/mesh/D007948", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe monoblastique", "code": { "@type": "MedicalCode", "code": "D007948", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.484" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aiguë promyélocytaire", "alternateName": "Leukemia, Promyelocytic, Acute", "url": "https://questionsmedicales.fr/mesh/D015473", "about": { "@type": "MedicalCondition", "name": "Leucémie aiguë promyélocytaire", "code": { "@type": "MedicalCode", "code": "D015473", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.275.700" } } }, { "@type": "MedicalWebPage", "name": "Leucémie aigüe myélomonocytaire", "alternateName": "Leukemia, Myelomonocytic, Acute", "url": "https://questionsmedicales.fr/mesh/D015479", "about": { "@type": "MedicalCondition", "name": "Leucémie aigüe myélomonocytaire", "code": { "@type": "MedicalCode", "code": "D015479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.337.539.520" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Leucémies", "alternateName": "Leukemia", "code": { "@type": "MedicalCode", "code": "D007938", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Kumaran Mudaliar", "url": "https://questionsmedicales.fr/author/Kumaran%20Mudaliar", "affiliation": { "@type": "Organization", "name": "Department of Pathology and Laboratory Medicine Loyola University Medical Center Maywood Illinois USA." } }, { "@type": "Person", "name": "Gregor Eisenwort", "url": "https://questionsmedicales.fr/author/Gregor%20Eisenwort", "affiliation": { "@type": "Organization", "name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria." } }, { "@type": "Person", "name": "Irina Sadovnik", "url": "https://questionsmedicales.fr/author/Irina%20Sadovnik", "affiliation": { "@type": "Organization", "name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria." } }, { "@type": "Person", "name": "Alexandra Keller", "url": "https://questionsmedicales.fr/author/Alexandra%20Keller", "affiliation": { "@type": "Organization", "name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria." } }, { "@type": "Person", "name": "Daniela Berger", "url": "https://questionsmedicales.fr/author/Daniela%20Berger", "affiliation": { "@type": "Organization", "name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Recommendations for the Use of in Silico Approaches for Next-Generation Sequencing Bioinformatic Pipeline Validation: A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists.", "datePublished": "2022-10-13", "url": "https://questionsmedicales.fr/article/36244574", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jmoldx.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "Houston Methodist cardiovascular learning health system (CVD-LHS) registry: Methods for development and implementation of an automated electronic medical record-based registry using an informatics framework approach.", "datePublished": "2024-04-30", "url": "https://questionsmedicales.fr/article/38756692", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajpc.2024.100678" } }, { "@type": "ScholarlyArticle", "name": "Metadata Correction: Identifying Contextual Factors and Strategies for Practice Facilitation in Primary Care Quality Improvement Using an Informatics-Driven Model: Framework Development and Mixed Methods Case Study.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35802904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/40674" } }, { "@type": "ScholarlyArticle", "name": "Leveraging Clinical Informatics and Data Science to Improve Care and Facilitate Research in Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference.", "datePublished": "2023-01-20", "url": "https://questionsmedicales.fr/article/36661432", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/PCC.0000000000003155" } }, { "@type": "ScholarlyArticle", "name": "Evaluating and Enhancing the Fitness-for-Purpose of Electronic Health Record Data: Qualitative Study on Current Practices and Pathway to an Automated Approach Within the Medical Informatics for Research and Care in University Medicine Consortium.", "datePublished": "2024-08-19", "url": "https://questionsmedicales.fr/article/39158950", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/57153" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://questionsmedicales.fr/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs par type histologique", "item": "https://questionsmedicales.fr/mesh/D009370" }, { "@type": "ListItem", "position": 4, "name": "Leucémies", "item": "https://questionsmedicales.fr/mesh/D007938" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Leucémies - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Leucémies", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Leucémies", "description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour confirmer une leucémie ?\nQuels signes indiquent une leucémie lors des tests ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie médullaire ?", "url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Informatics&page=45#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Leucémies", "description": "Quels sont les symptômes courants de la leucémie ?\nLa perte de poids est-elle un symptôme de leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nLes douleurs osseuses sont-elles liées à la leucémie ?\nLes sueurs nocturnes sont-elles un symptôme ?", "url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Informatics&page=45#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Leucémies", "description": "Peut-on prévenir la leucémie ?\nQuels facteurs de risque sont associés à la leucémie ?\nLe tabagisme augmente-t-il le risque de leucémie ?\nLes infections virales peuvent-elles causer la leucémie ?\nL'alimentation joue-t-elle un rôle dans la prévention ?", "url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Informatics&page=45#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Leucémies", "description": "Quels sont les traitements principaux de la leucémie ?\nLa chimiothérapie est-elle efficace contre toutes les leucémies ?\nQu'est-ce qu'une greffe de moelle osseuse ?\nQuels sont les effets secondaires de la chimiothérapie ?\nLa radiothérapie est-elle utilisée pour traiter la leucémie ?", "url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Informatics&page=45#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Leucémies", "description": "Quelles sont les complications possibles de la leucémie ?\nComment la leucémie affecte-t-elle la coagulation sanguine ?\nLes leucémies peuvent-elles entraîner des problèmes cardiaques ?\nQuelles infections sont fréquentes chez les patients leucémiques ?\nLes leucémies peuvent-elles causer des douleurs chroniques ?", "url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Informatics&page=45#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Leucémies", "description": "Quels sont les principaux facteurs de risque de leucémie ?\nL'âge influence-t-il le risque de leucémie ?\nLes troubles génétiques augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de leucémie ?\nLes antécédents de chimiothérapie augmentent-ils le risque ?", "url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Informatics&page=45#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une leucémie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des examens d'imagerie." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer une leucémie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'hémogramme, la cytométrie en flux et les tests génétiques." } }, { "@type": "Question", "name": "Quels signes indiquent une leucémie lors des tests ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une augmentation des globules blancs, une anémie et des plaquettes basses peuvent indiquer une leucémie." } }, { "@type": "Question", "name": "Les examens d'imagerie sont-ils nécessaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens comme la radiographie ou l'IRM peuvent aider à évaluer l'extension de la maladie." } }, { "@type": "Question", "name": "Quelle est l'importance de la biopsie médullaire ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie médullaire permet d'évaluer la présence de cellules leucémiques dans la moelle osseuse." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la leucémie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements faciles." } }, { "@type": "Question", "name": "La perte de poids est-elle un symptôme de leucémie ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une perte de poids inexpliquée peut être un symptôme de leucémie." } }, { "@type": "Question", "name": "Comment la leucémie affecte-t-elle le système immunitaire ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La leucémie affaiblit le système immunitaire, rendant le corps plus vulnérable aux infections." } }, { "@type": "Question", "name": "Les douleurs osseuses sont-elles liées à la leucémie ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs osseuses peuvent survenir en raison de l'accumulation de cellules leucémiques." } }, { "@type": "Question", "name": "Les sueurs nocturnes sont-elles un symptôme ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les sueurs nocturnes peuvent être un symptôme courant chez les patients leucémiques." } }, { "@type": "Question", "name": "Peut-on prévenir la leucémie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention garantie, mais éviter les facteurs de risque peut aider." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à la leucémie ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'exposition aux radiations, certains produits chimiques et des maladies génétiques." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque de leucémie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque connu pour certains types de leucémie." } }, { "@type": "Question", "name": "Les infections virales peuvent-elles causer la leucémie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à un risque accru de leucémie." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut contribuer à la santé générale, mais ne prévient pas spécifiquement la leucémie." } }, { "@type": "Question", "name": "Quels sont les traitements principaux de la leucémie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chimiothérapie, la radiothérapie et la greffe de moelle osseuse." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace contre toutes les leucémies ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie est efficace pour de nombreux types de leucémie, mais pas tous." } }, { "@type": "Question", "name": "Qu'est-ce qu'une greffe de moelle osseuse ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "C'est un traitement qui remplace la moelle osseuse malade par des cellules souches saines." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la chimiothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée pour traiter la leucémie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut être utilisée pour traiter certaines leucémies, surtout en cas de complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de la leucémie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent infections graves, saignements, et complications liées aux traitements." } }, { "@type": "Question", "name": "Comment la leucémie affecte-t-elle la coagulation sanguine ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La leucémie peut entraîner des troubles de la coagulation, augmentant le risque de saignements." } }, { "@type": "Question", "name": "Les leucémies peuvent-elles entraîner des problèmes cardiaques ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements de la leucémie peuvent augmenter le risque de problèmes cardiaques." } }, { "@type": "Question", "name": "Quelles infections sont fréquentes chez les patients leucémiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les infections bactériennes et fongiques sont courantes en raison d'un système immunitaire affaibli." } }, { "@type": "Question", "name": "Les leucémies peuvent-elles causer des douleurs chroniques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les douleurs chroniques peuvent survenir en raison de la maladie ou des traitements." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque de leucémie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux facteurs incluent l'exposition aux radiations, certains produits chimiques et des antécédents familiaux." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de leucémie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de leucémie augmente avec l'âge, surtout après 60 ans." } }, { "@type": "Question", "name": "Les troubles génétiques augmentent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles comme le syndrome de Down augmentent le risque de leucémie." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque de leucémie ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les hommes ont généralement un risque plus élevé de leucémie que les femmes." } }, { "@type": "Question", "name": "Les antécédents de chimiothérapie augmentent-ils le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, avoir reçu une chimiothérapie pour un autre cancer peut augmenter le risque de leucémie." } } ] } ] }

Sources (450 au total)

Recommendations for the Use of in Silico Approaches for Next-Generation Sequencing Bioinformatic Pipeline Validation: A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists.

In silico approaches for next-generation sequencing (NGS) data modeling have utility in the clinical laboratory as a tool for clinical assay validation. In silico NGS data can take a variety of forms,...

Houston Methodist cardiovascular learning health system (CVD-LHS) registry: Methods for development and implementation of an automated electronic medical record-based registry using an informatics framework approach.

To investigate the potential value and feasibility of creating a listing system-wide registry of patients with at-risk and established Atherosclerotic Cardiovascular Disease (ASCVD) within a large hea... We conducted a retrospective multi-center, cohort analysis of adult patients who were seen in the outpatient settings of a large healthcare system between June 2016 - December 2022 to create an EMR-ba... A real-time, programmatically deidentified, auto-updated EMR-based HM CVD-LHS registry was developed with ∼450 variables stored in multiple tables each containing information related to patient's demo... HM CVD-LHS registry database was developed successfully providing the listing registry of patients with established ASCVD and those at risk. This approach empowers knowledge inference and provides sup...

Leveraging Clinical Informatics and Data Science to Improve Care and Facilitate Research in Pediatric Acute Respiratory Distress Syndrome: From the Second Pediatric Acute Lung Injury Consensus Conference.

The use of electronic algorithms, clinical decision support systems, and other clinical informatics interventions is increasing in critical care. Pediatric acute respiratory distress syndrome (PARDS) ... MEDLINE (Ovid), Embase (Elsevier), and CINAHL Complete (EBSCOhost).... We included studies of pediatric or adult critically ill patients with or at risk of ARDS that examined automated screening tools, electronic algorithms, or clinical decision support systems.... Title/abstract review, full text review, and data extraction using a standardized data extraction form.... The Grading of Recommendations Assessment, Development and Evaluation approach was used to identify and summarize evidence and develop recommendations. Twenty-six studies were identified for full text... We present two clinical recommendations and three statements (two research one policy) for the use of electronic algorithms and clinical informatics tools for patients with PARDS based on a systematic...

Evaluating and Enhancing the Fitness-for-Purpose of Electronic Health Record Data: Qualitative Study on Current Practices and Pathway to an Automated Approach Within the Medical Informatics for Research and Care in University Medicine Consortium.

Leveraging electronic health record (EHR) data for clinical or research purposes heavily depends on data fitness. However, there is a lack of standardized frameworks to evaluate EHR data suitability, ... The study aims (1) to capture and discuss how MIRACUM DICs evaluate and enhance the fitness-for-purpose of observational health care data and examine the alignment with existing recommendations and (2... A qualitative approach was followed using an open-ended survey across DICs of 10 German university hospitals affiliated with MIRACUM. Data were analyzed using thematic analysis following an inductive ... All 10 MIRACUM DICs participated, with 17 participants revealing various approaches to assessing data fitness, including the 4-eyes principle and data consistency checks such as cross-system data valu... The study identifies gaps between current practices in MIRACUM DICs and existing recommendations, offering insights into the complexities of assessing and reporting clinical data fitness. Additionally...

Secondary use of health care data and left-over biosamples within the 'Medical Informatics Initiative' (MII): a quasi-randomized controlled evaluation of patient perceptions and preferences regarding the consent process.

Data collected during routine health care and ensuing analytical results bear the potential to provide valuable information to improve the overall health care of patients. However, little is known abo... We performed a quasi-randomized controlled trial and compared the method by which patients were informed either in the patient admission area following patient admission by the same staff member (Grou... Questionnaire data were obtained from 157 participants in Group A and 106 participants in Group B. Overall, participants in both groups were satisfied with their experienced process and with the way i... The willingness to support medical research by allowing the use of routine data and left-over samples seems to be widespread among patients. Information concerning this secondary data use may be given...

Initiation of glucocorticoids before entering rheumatology care associates with long-term glucocorticoid use in older adults with early rheumatoid arthritis: A joint analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) data.

To assess relationships between the timing of glucocorticoid (GC) initiation, entrance into rheumatology care, and the duration of GC use in older adults with early rheumatoid arthritis (eRA) in the U... Data from the Rheumatology Informatics System for Effectiveness (RISE) registry and Medicare (2016-2018) were linked. Patients with ≥2 RA ICD codes in RISE were included; the first being the index dat... 1,733 patients (67 % female; mean age 76 ± 6 years) were included. 41 % initiated GCs, on average 16 ± 58 days before entering rheumatologic care. The mean duration of GC use was 157 days (95 %-CI 143... GCs are regularly used in eRA and most often initiated before patients enter rheumatology care. Long-term, low-dose GC use is common and associated with initiation before rheumatology care. Earlier re...